Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines

A compound in accordance with formula I

• wherein:
• X is N or CR14;
• R1 is selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, (C3-C10cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, halo, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7;
• C1-C6 cyanoalkyl, NR8R9, C1-C6 alkyl-NR8R9;
• R2 is H, C1-C6 alkyl which optionally forms a C3-C6 aminocarbocycle or a C2-C5 aminoheterocycle with A or B, each of which is optionally substituted at each occurrence with R7, C3-C10 cycloalkyl, or (C3-C10 cycloalkyl) C1-C6 alkyl;
• or
• R2 and R6 jointly form with the 2 nitrogen atoms to which they are bound, form a C2-C5 aminoheterocycle optionally substituted at each occurrence with R7;
• A is (CH2)m, where m is 1, 2 or 3 and is optionally mono- or di-substituted on each occurrence with C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, halo, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7;
• C1-C6 cyanoalkyl, NR8R9, C1-C6 alkyl-NR8R9;
• or
• A and B jointly form a C3-C6 carbocycle, optionally substituted at each occurrence with R7;
• or
• A and R2 jointly form a C3-C6 aminocarbocycle or a C2-C5 aminoheterocycle optionally substituted at each occurrence with R7;
• B is (CH2)n, where n is 1, 2 or 3 and is optionally mono- or di-substituted on each occurrence with C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, halo, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7;
• C1-C6 cyanoalkyl, NR8R9, and C1-C6 alkyl-NR8R9;
• or, as mentioned above,
• B and A jointly form a C3-C6 carbocycle, optionally substituted at each occurrence with R7;
• as mentioned above,
• B and R2 jointly form a C3-C6 aminocarbocycle or a C2-C5 aminoheterocycle optionally substituted at each occurrence with R7;
• R3 is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, halo, C1-C6 haloalkyl, OR7, C1-C6 cyanoalkyl, NR8R9, C1-C6 alkyl-NR8R9;
• R4 is selected from aryl or heteroaryl, each of which is substituted with 1 to 5 substituents independently selected from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, halogen, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7, NR8R9, C1-C6 alkyl-NR8R9, CONR8R9, C1-C6 alkyl-CONR8R9, COOR7, C1-C6 alkyl-COOR7, CN, C1-C6 alkyl-CN, SO2NR8R9, SO2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein at least one of the positions ortho or para to the point of attachment of the aryl or heteroaryl ring to the pyrazole is substituted;
• R5 is selected from:
• C1-C6 alkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, each of which is substituted with 1 to 5 groups independently selected at each occurrence from halo, C1-C2 haloalkyl, oxo, OR7, cyano, NR8R9, CONR8R9, COOR7, SO12NR11R9, SO2R7, NR11COR2, NR8SO2R7;
• or
• Aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C5-C8)cycloalkyl, or heteroaryl(C5-C8)cycloalkyl, where aryl is phenyl or naphthyl, and heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4-, 5-pyrimidinyl, triazinyl, 1-, 2-, or 4-imidazolyl 2-, 4-, or 5-oxazolyl isoxazolylindolyl, pyrazolyl, quinolyl, isoquinolyl, 2-, 4-, or 5-thiazolyl, benzothiadiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-triazinyl, 2-pyrazinyl, 2-, or 3-furanyl, 2-, or 3-thienyl, 2-, or 3-benzothienyl, or 1-, 2- or 5 tetrazolyl, each of which is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10, cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C6 alkenyl, halogen, C1-C6 haloalkyl, OR7, NR8R9, C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, SO2NR8R9, SO2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents may be take together to form a C3-C10 cycloalkyl ring, a C3-C10 cycloalkenyl ring or a heterocycloalkyl ring;
• or
• C3-C10 cycloalkyl substituted with 1 to 6 substituents independently selected from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C6 alkenyl, oxo, halogen, C1-C6 haloalkyl, OR7, NR8R9, (with the proviso that when two OR7 or NR8R9 substituents are geminally located on the same carbon R7 is not H and the geminally located OR7 or NR8R9 substituents can be taken together to form a C2-C4 ketal, oxazoline, oxazolidine, imidazoline, or imidazolidine heterocycle), C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, oxo, hydroximino, C1-C6 alkoximino, SO2NR8R9, SO2R7, heterocycloalkyl, aryl, heteroaryl, where aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C6 alkenyl, halogen, C1-C6 haloalkyl, OR7, NR8R9, C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN SO2NR8R9, SO2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C3-C10 cycloalkyl ring, a C3-C10 cycloalkenyl ring or a heterocycloalkyl ring;
• or
• aryl or heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from halogen, C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C6 alkenyl, halogen, C1-C6 haloalkyl, OR7, NR8R9, C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, SO2NR8R9, SO2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents may be taken together to form a C3-C10 cycloalkyl ring, a C3-C10 cycloalkenyl ring or a heterocycloalkyl ring;
• or
• 3- or 4-piperidinyl, 3-pyrrolidinyl, 3- or 4- tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4- tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4-tetrahydrothiopyranyl, 3- or 4-(11-dioxo) tetrahydrothiopyranyl, 1-azabicyclo[4.4.0]decyl, 8-azabicyclo[3.2.1]octanyl, norbornyl, quinuclidinyl, indolin-2-one-3-yl, 2-(methoximino)-perhydroazepin-6-yl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from R7, C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, CN, COOR7 SO2NR8R9, and SO2R7;
• R6 is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C4 alkenyl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl each of which is optionally substituted with 1 to 5 substituents independently from halogen, C1-C6 haloalkyl, OR13, NR8R9, C1-C6 alkyl-OR13, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, SO2NR8R9, and SO2R7;
• or
• R6 and R2 jointly form with the two nitrogens to which they are bound a C2-C5 aminoheterocycle optionally substituted at each occurrence by R7;
• R7 is independently selected at each occurrence from H, C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C3 haloalkyl, or heterocycloalkyl, C1-C8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C1-C8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C1-C6 arylalkyl or C1-C6 heteroarylalkyl each optionally substituted with 1 to 5 substituents independently selected from halogen, C1-C6 haloalkyl, OR13, NR8R9, C1-C6 alkyl-OR13, C1-C6 alkyl-NR8R9, CONR8R9, COOR13, CN, SO2NR8R9, and SO2R13, with the proviso that when R7 is SO2R13, R13 cannot be H;
• R8 and R9 are independently selected at each occurrence from H, C1-C6 alkyl, C3-C10 cycloalkyl, C2-C6 alkenyl, C3-C10 cycloalkenyl, C2-C6 alkynyl, heterocycloalkyl, C1-C8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C1-C6 arylalkyl or C1-C6 heteroarylalkyl, or R8 and R9, taken together, can form a C3-C6 aminocarbocycle or a C2-C5 aminoheterocycle each of which is optionally substituted with C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C3 haloalkyl, or heterocycloalkyl, C1-C8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C1-C8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C1-C6 arylalkyl or C1-C6 heteroarylalkyl;
• R11 is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl;
• R12 is selected from H, aryl, heteroaryl, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, optionally substituted with OR7, NR8R9, C3-C6 aminocarbocycle, or C2-C5 aminoheterocycle;
• R13 is independently selected at each occurrence from H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, with the proviso that when R7 is SO2R13, R13 cannot be H;
• and
• R14 is H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halo, or CN or a pharmaceutically acceptable salt, hydrate or prodrug thereof.

A compound in accordance with formula I

• or a pharmaceutically acceptable salt, hydrate or prodrug thereof wherein:
• X is N or CR14;
• R1 is selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, (C3-C10cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, halo, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7;
• C1-C6 cyanoalkyl, NR8R9, C1-C6 alkyl-NR8R9;
• R2 is H, C1-C6 alkyl, C3-C10 cycloalkyl, or (C3-C10 cycloalkyl) C1-C6 alkyl, wherein each alkyl or cycloalkyl group may be optionally substituted with 1 to 3 R7a groups;
• or
• R2 may optionally join with R5 and the two and the 2 nitrogen atoms to which they are bound to form a 6 to 10 membered heterocyclic ring optionally substituted at each carbon with R7a;
• or
• R2 and A may optionally join to form a 3 to 8 membered heterocyclic ring optionally substituted at each carbon with R7a;
• or
• R2 and B optionally join to form a 4 to 10 membered heterocyclic ring optionally substituted at each carbon with R7a;
• A represents an alkyl chain of 1, 2 or 3 carbon atoms which is optionally mono- or di-substituted at each carbon with substituents independently selected from C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, halo, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7;
• C1-C6 cyanoalkyl, NR8R9, C1-C6 alkyl-NR8R9;
• or
• A and B jointly form a C3-C6 carbocycle, optionally substituted at each occurrence with R7a;
• B represents an alkyl chain of 1, 2 or 3 carbon atoms, which is optionally mono- or di- substituted at each carbon with substituents independently selected from C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, halo, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7;
• C1-C6 cyanoalkyl, NR8R9, and C1-C6 alkyl-NR8R9;
• or
• B and R5 may jointly form a 4 to 7 membered heterocyclic ring, which is optionally substituted at each atom with R7a;
• R3 is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, halo, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7, C1-C6 cyanoalkyl, NR8R9, C1-C6 alkyl-NR8R9;
• R4 is selected from aryl or heteroaryl, each of which is substituted with 1 to 5 substituents independently selected from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, halogen, C1-C6 haloalkyl, OR7, C1-C6 alkyl-OR7, NR8R9, C1-C6 alkyl-NR8R9, CON8R9, C1-C6 alkyl-CONR8R9, COOR7, C1-C6 alyl-COOR7, CN, C1-C6 alkyl-CN, SO2NR8R9, SO2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), C2-C4 alkynyl wherein at least one of the positions ortho or para to the point of attachment of the aryl or heteroaryl ring to the pyrazole is substituted;
• R5 is selected from:
• C1-C6 alkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, each of which is substituted with 1 to 5 groups independently selected at each occurrence from C1-C6 alkyl, C3-C10 , cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6, alkenyl halogen, C1-C6 haloalkyl, OR7, NR8R9, (with the proviso that when two OR7 or NR8R9 substituents are geminally located on the same carbon R7 is not H and the geminally located OR7 or NR8R9 substituents can be taken together to form a C2-C4 ketal, oxazoline, oxazolidine, imidazoline, or imidazolidine heterocycle), C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, oxo, hydroximino, C1-C6 alkoximino, SO2NR8R9, SO2R7, heterocycloalkyl, aryl, heteroaryl, where aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl), C1-C6 alkyl, C2-C6 alkenyl, halogen, C1-C6 haloalkyl, OR7, NR8R9, C1-C6 alkyl-OR[7]7, C1-C6 alkyl NR8R9, CONR8R9, COOR7, CN, SO2NR8R9, SO2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C3-C10, cycloalkyl ring, a C3-C10 cycloalkenyl ring or a heterocycloalkyl ring;
• with the proviso that C1-C6 alkyl group is substituted with a C1-C6 alkyl group to give a C7-C10 alkyl group;
• or
• Aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, aryl(C5-C8)cycloalkyl, or heteroaryl(C5-C8)cycloalkyl, each of which is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C6 alkenyl, halogen, C1-C6 haloalkyl, OR7, NR8R9, C1-C6 alkyl-OR7, C7-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, SO2NR8R9, SO2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents may be take together to form a C3-C10 cycloalkyl ring, a C3-C10 cycloalkenyl ring or a heterocycloalkyl ring;
• or
• C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 cycloalkenyl, or a 3 to 10 membered mono- or bicyclic heterocycle containing 1-3 O, S or N atoms, each of which is substituted with 1 to 6 substituents independently selected from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, halogen, C1-C6 haloalkyl, OR7, NR8R9, (with the proviso that when two OR7 or NR8R9 substituents are geminally located on the same carbon R7 is not H and the geminally located OR7 or NR8R9 substituents can be taken together to form a C2-C4 ketal, oxazoline, oxazolidine, imidazoline, or imidazolidine heterocycle), C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, oxo hydroximino, C1-C6 alkoximino, SO2NR8R9, SO2R7, COR7, heterocycloalkyl, aryl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl where aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C1-cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, halogen, C1-C6 haloalkyl, OR7, NR8R9, C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN SO2NR8R9, SO2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C3-C10 cycloalkyl ring, a C3-C10 cycloalkenyl ring or a heterocycloalkyl ring;
• or
• aryl or heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from halogen, C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, halogen, C1-C6 haloalkyl, OR7, NR8R9, C1-C6 alkyl-OR7, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, SO2NR8R9, S[0]O[2]2R7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents maybe taken together to form a C3-C10 cycloalkyl ring, a C3-C10 cycloalkenyl ring or a heterocycloalkyl ring;
• R6 is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C4 alkenyl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl each of which is optionally substituted with 1 to 5 substituents independently from halogen, C1-C6 haloalkyl, OR13, NR8R9, C1-C6 alkyl-OR13, C1-C6 alkyl-NR8R9, CONR8R9, COOR7, CN, SO2NR8R9, and SO2R7;
• R7 is independently selected at each occurrence from H, C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C3 haloalkyl, or heterocycloalkyl, aryl, heteroaryl, C1-C6 arylalkyl or C1-C6 heteroarylalkyl each optionally substituted with 1 to 5 substituents independently selected from halogen, C1-C6 haloalkyl, OR13, NR8R9, C1-C6 alkyl-OR13, C1-C6 alkyl-NR8R9, CONR8R9, COOR13, CN, SO2NR8R9, and SO2R13;
• R7ais independently selected at each occurrence from H, C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C3 haloalkyl, or heterocycloalkyl, C1-C8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C1-C8 alkanoyl, aryl, heteroaroyl, aryl, heteroaryl, C1-C6 arylalkyl or C1-C6 heteroarylalkyl each optionally substituted with 1 to 5 substituents independently selected from halogen, C1-C6 haloalkyl, OR13, NR8R9, C1-C6 alkyl-OR13, C1-C6 alkyl-NR8R9, CONR8R9, COOR13, CN, SO2NR8R9, and SO2R13, with the proviso that when R7ais SO2R13, R13 cannot be H;
• R8 and R9 are independently selected at each occurrence from H, C1-C6 alkyl, C3-C10 cycloalkyl, C2-C6 alkenyl, C3-C10 cycloalkenyl, C2-C6 alkynyl, heterocycloalkyl, C1-C8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C1-C6 arylalkyl or C1-C6 heteroarylalkyl, or R8 and R9 taken together can form a C3-C6 aminocarbocycle or a C2-C5 aminoheterocycle each of which is optionally substituted with C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C1-C3 haloalkyl, or heterocycloalkyl, C1-C8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C1-C8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C1-C6 arylalkyl or C1-C6 heteroarylalkyl;
• R11 is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl;
• R12 is selected from H, aryl, heteroaryl, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, optionally substituted with OR7, NR8R9, C3-C6 amninocarbocycle, or C2-C5 aminoheterocycle;
• R13 is independently selected at each occurrence from H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, with the proviso that when R7 is SO2R13, R13 cannot be H;
• and
• R14 is H, C1-C6 alkyl, C3-C10 cycloalkyl, (C3-C10 cycloalkyl) C1-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halo, or CN.